Should Investors Be Worried About Biogen's Alzheimer's Drug?
On Dec. 5, Biogen (NASDAQ: BIIB) announced its initial phase 3 trial results for its late-stage Alzheimer's drug candidate, aducanumab. While the results weren't entirely negative, investors who had high hopes for the drug were disappointed by less-than-stellar results.
Since then, several analysts downgraded Biogen's stock, claiming this new data is too ambiguous to warrant approval from the U.S. Food and Drug Administration. Let's take a further look at these results, what it means for Biogen, and what biotech investors should do in regard to this company.
Image sources: Getty Images.
Source Fool.com
